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Pemphigus vulgaris (PV) is an autoimmune blistering disease of skin and mucous
membranes caused by autoantibodies to the desmoglein (DSG) family proteins DSG3 and
DSG1, leading to loss of keratinocyte cell adhesion. To learn more about pathogenic PV
autoantibodies, we isolated 15 IgG antibodies specific for DSG3 from 2 PV patients. Three
antibodies disrupted keratinocyte monolayers in vitro, and 2 were pathogenic in a passive
transfer model in neonatal mice. The epitopes recognized by the pathogenic antibodies
were mapped to the DSG3 extracellular 1 (EC1) and EC2 subdomains, regions involved in
cis-adhesive interactions. Using a site-specific serological assay, we found that the cis-
adhesive interface on EC1 recognized by the pathogenic antibody PVA224 is the primary
target of the autoantibodies present in the serum of PV patients. The autoantibodies isolated
used different heavy- and light-chain variable region genes and carried high levels of
somatic mutations in complementary-determining regions, consistent with antigenic
selection. Remarkably, binding to DSG3 was lost when somatic mutations were reverted to
the germline sequence. These findings identify the cis-adhesive interface of DSG3 as the
immunodominant region targeted by pathogenic antibodies in PV and indicate that
autoreactivity relies on somatic mutations generated in the response to an antigen unrelated
to DSG3.
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Pemphigus vulgaris (PV) is an autoimmune blistering disease of skin and mucous membranes caused by auto-
antibodies to the desmoglein (DSG) family proteins DSG3 and DSG1, leading to loss of keratinocyte cell adhe-
sion. To learn more about pathogenic PV autoantibodies, we isolated 15 IgG antibodies specific for DSG3 from 
2 PV patients. Three antibodies disrupted keratinocyte monolayers in vitro, and 2 were pathogenic in a passive 
transfer model in neonatal mice. The epitopes recognized by the pathogenic antibodies were mapped to the 
DSG3 extracellular 1 (EC1) and EC2 subdomains, regions involved in cis-adhesive interactions. Using a site-spe-
cific serological assay, we found that the cis-adhesive interface on EC1 recognized by the pathogenic antibody 
PVA224 is the primary target of the autoantibodies present in the serum of PV patients. The autoantibodies 
isolated used different heavy- and light-chain variable region genes and carried high levels of somatic mutations 
in complementary-determining regions, consistent with antigenic selection. Remarkably, binding to DSG3 was 
lost when somatic mutations were reverted to the germline sequence. These findings identify the cis-adhesive 
interface of DSG3 as the immunodominant region targeted by pathogenic antibodies in PV and indicate that 
autoreactivity relies on somatic mutations generated in the response to an antigen unrelated to DSG3.
Introduction
Pemphigus vulgaris (PV) is a life-threatening autoimmune blis-
tering disease of skin and mucous membranes caused by auto-
antibodies that bind to the cadherin-type cell-cell adhesion mol-
ecules desmoglein 3 (DSG3) and DSG1, the main constituents 
of desmosomes, and cause the loss of keratinocyte cell adhesion 
(1). The critical role of autoantibodies in PV pathogenesis is sup-
ported by the observations that the disease activity correlates 
with anti-DSG3 antibody titers (2), that newborns of mothers 
with active PV exhibit blisters caused by the placental transfer 
of maternal antibodies (3), and that pemphigus-like lesions are 
induced in neonatal mice by passive transfer of anti-DSG3 IgG 
from PV patients (4).
In the skin, DSG3 is mainly expressed in the basal and suprabas-
al layers (5), while DSG1 is predominantly expressed in the upper 
epidermal layers. In contrast, in noncornified stratified epithelia, 
such as the oral mucosa, DSG3 is highly expressed throughout 
the epithelium, while DSG1 is expressed at a much lower level. 
The differential expression pattern of DSG1 and DSG3 is respon-
sible for clinical variants of pemphigus (6): antibodies to DSG3 
are present in the mucosal form, while antibodies to both DSG3 
and DSG1 are associated with mucocutaneous lesions (7).
DSG3 is a calcium-binding membrane glycoprotein with an 
extracellular domain comprising 5 distinct subdomains (EC1–
EC5), and it is synthesized as proprotein, which is processed in 
the Golgi apparatus by removal of a propeptide before trans-
porting to the cell surface. The cleavage of the propeptide occurs 
upstream of a conserved tryptophan residue in the EC1 subdo-
main, unmasking residues critical for the formation of homo-
philic interactions with DSG3 on opposing cells (8, 9). Several 
studies have shown that polyclonal antibodies in PV serum react 
primarily with the aminoterminus of DSG3 in the EC1 and EC2 
subdomains (amino acids 1–161) (10, 11).
The isolation of pathogenic mAbs is instrumental for address-
ing questions as to the mechanism that induces the autoreactive 
response and drives blister formation in PV patients. Amagai and 
coworkers isolated from an active mouse model of PV a patho-
genic antibody, AK23, which causes loss of cell adhesion by bind-
ing to the EC1 subdomain of DSG3 that is involved in the forma-
tion of the trans-adhesive interface (12, 13). A number of human 
anti-DSG pathogenic and nonpathogenic mAbs were isolated as 
single-chain variable-region fragments (scFvs) from a PV patient 
(14). Similarly to the AK23 mAb, the pathogenic activity of these 
human antibodies was mapped to the aminoterminal region of 
EC1, which is masked by the propeptide (9, 13, 14). Taken together, 
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the human and mouse data suggest that pathogenic antibodies 
bind primarily to EC1 and disrupt the keratinocyte adhesion by 
interfering with the trans-adhesive interface of DSG3.
In this study, we isolated from 2 PV patients several IgG autoan-
tibodies that bind DSG3. These antibodies carried high levels of 
somatic mutations that were required for binding to DSG3. The 
epitopes recognized by 3 pathogenic antibodies were mapped to 
the EC1 and EC2 subdomains in regions that are expected to be 
involved in cis-adhesive interactions. This region was found to be 
the primary target of serum autoantibodies in PV patients. These 
results identify the cis-adhesive interface as the immunodominant 
region targeted by pathogenic antibodies in PV and suggest that 
autoreactivity relies on somatic mutations triggered by an unre-
lated antigen.
Results
Isolation and characterization of DSG3-specific antibodies from PV 
patients. Peripheral blood samples were collected from 2 patients 
with mucocutaneous PV: one with long-lasting steroid-resistant 
disease (PVA) and the other prior to treatment initiation (PVB). 
IgG+ memory B cells were isolated by a combination of magnetic- 
and fluorescence-activated cell sorting, seeded in 96-well micro-
plates, and immortalized with EBV in the presence of irradiated 
mononuclear cells and oligodeoxynucleotides containing CpG 
motifs, as previously described (15). Culture supernatants were 
screened using DSG3-ELISA and indirect immunofluorescence 
(IF) staining of live keratinocyte monolayers. Cultures that pro-
duced specific antibodies were cloned by limiting dilution, and 
15 independent clones were isolated and characterized (Table 1). 
Three of the 6 antibodies from patient PVA and all the 9 antibod-
ies isolated from patient PVB bound to DSG3, while 3 antibodies 
from PVA crossreacted with both DSG3 and DSG1. All antibodies 
showed the characteristic fishnet intercellular staining of epitheli-
al cells on human skin and monkey esophagus (Figure 1A and data 
not shown). In addition, 11 out of the 15 antibodies failed to bind 
to DSG3 in the presence of EDTA, as assessed by IF and ELISA 
(Figure 1, B and C), consistent with the recognition of calcium-
dependent conformational epitopes.
Consistent with previous reports (16, 17), the antibodies were 
primarily IgG1 or IgG4, although IgG2 and IgG3 antibodies were 
also isolated. The antibodies used different genes encoding the 
immunoglobulin variable regions of heavy (VH) and light (VL) 
chains, with a slight bias toward VH3 and VH4, carried heavy 
chain complementarity-determining region 3 (H-CDR3) and 
light chain complementarity-determining region 3 (L-CDR3) of 
different lengths (10–21 and 8–11 amino acids, respectively), and 
had a variable load of somatic mutations (Table 1). A higher level 
of replacing mutations was found in CDRs of both VH and VL 
(Supplemental Figure 1, A and B; supplemental material available 
online with this article; doi:10.1172/JCI64413DS1). The somatic 
mutations in VH and VL gene segments were analyzed using the 
implemented Focused binomial test and the Global binomial test 
(18, 19), which compare the observed frequency of replacement 
mutations with their expected frequency under the null hypoth-
esis of no selection. This analysis showed for most antibodies a 
trend for positive antigenic selection in the CDRs of heavy and/or 
light chains, which was comparable to that observed in virus-neu-
tralizing antibodies (Supplemental Table 1 and data not shown). 
Alignment of the H-CDR3 sequences did not reveal shared motifs, 
but identified an aromatic cluster (YYYYF) at the tip of H-CDR3 
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of the PVA224 antibody (Supplemental Figure 2). Taken together, 
our data indicate that in PV patients, the DSG3 antibody response 
is polyclonal, is not biased toward a particular V gene, and is likely 
to be antigen selected.
DSG3 subdomain specificity and pathogenic activity of autoantibodies. 
To grossly map the targets of the autoantibodies isolated, we used 
chimeric DSG2 molecules containing DSG3 subdomains (20) 
and measured the ability of these molecules to inhibit binding of 
the autoantibodies to DSG3-coated plates. Using this assay, we 
found that the antibodies from patient PVA mapped to different 
DSG3 subdomains (EC1, EC2, EC3, or EC5), while 7 out of the 9 
antibodies from patient PVB targeted the EC2 subdomain and 2 
recognized the EC5 subdomain (Figure 2A). The high prevalence 
of EC2-specific antibodies isolated from the PVB patient was par-
alleled by the predominant reactivity of PVB serum with EC2 in 
the same assay (Figure 2B).
To evaluate the pathogenicity of the isolated antibodies, we 
used an in vitro keratinocyte dissociation assay (21). Incubation 
of a confluent monolayer of human keratinocytes with pathogenic 
antibodies in the presence of exfoliative toxin A (ETA), which spe-
cifically cleaves DSG1, resulted in the fragmentation of the kera-
tinocyte sheet. The EC1-specific antibody PVA224 and, surpris-
ingly, 2 EC2-specific antibodies (PVB28 and PVB124) were able to 
dissociate the monolayer to an extent comparable to that of the 
reference mouse antibody AK23, while other EC2-, EC3-, and EC5-
specific antibodies were not effective (Figure 3, A and B).
To assess in vivo pathogenicity, we selected 2 antibodies (PVA224 
and PVB28) that were found to crossreact with mouse DSG3 and 
tested them in a mouse model of passively transferred PV (4). 
When injected subcutaneously into newborn mice together with 
ETA, PVA224 and PVB28 induced macroscopic blisters, intraepi-
dermal suprabasal blistering and acantholysis, and intercellular 
deposition of human IgG in the epidermis (Figure 3, C–E). As a 
control, antibodies PVB16 and PVB124, which do not recognize 
murine DSG3, did not cause macroscopic or microscopic blisters 
or IgG deposition in the epidermis. Taken together, the above find-
ings indicate that pathogenic antibodies bind to either EC1 or EC2 
subdomains and that, in addition to EC1-specific antibodies, a 
fraction of EC2-specific antibodies also have pathogenic activity.
Human pathogenic antibodies target the EC1-EC2 cis-adhesive DSG3 
interface. To gain insight into the epitope specificity and the mech-
anism of action of pathogenic antibodies, we performed a cross-
Figure 1
Human antibodies bind conformational epitopes in the DSG3 ectodo-
main. (A) Cryosections of human skin were stained with biotinylated 
human mAbs isolated from PV patients. Shown are 4 representative 
antibodies out of the 15 analyzed. The cutaneous basement membrane 
zone is marked by a dotted line. Scale bars: 100 μm. (B) Staining of 
human epidermis performed as in A with antibody PVB28 in the pres-
ence (with) or absence (w/o) of Ca+. Scale bars: 100 μm. (C) Binding 
of the indicated antibodies to DSG3-coated plates in the presence or 
absence of EDTA as assessed by ELISA. Data are representative of 2 
separate experiments (mean ± SEM).
Figure 2
DSG3 subdomain specificity of DSG3-specific autoantibodies. (A) 
Inhibition of mAb binding to coated DSG3 by chimeric molecules con-
sisting of DSG2 carrying a single DSG3 subdomain (EC1, EC2, EC3, 
EC4, or EC5). Black squares indicate a significant inhibition of antibody 
binding. Two mouse mAbs (mu-mAb), AK23 and RD, specific for EC1 
and EC5, respectively, were also analyzed. Results are representative 
of 2 independent experiments. (B) Inhibition of PVA and PVB serum 
antibody binding to coated DSG3 by chimeric DSG2–DSG3 molecules 
carrying the indicated DSG3 subdomains. Shown are mean values ± 
SEM of 2 independent experiments.
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competition assay for binding to DSG3-coated plates. Surprisingly, 
the pathogenic EC1-specific antibody PVA224 did not compete for 
binding with the mouse pathogenic antibody AK23, which has 
been shown to disrupt the EC1-EC1 trans-adhesion of DSG3 (refs. 
8, 9, 11, 13, and Supplemental Figure 3, A and B). This finding indi-
cates that the 2 pathogenic antibodies AK23 and PVA224 bind to 
nonoverlapping epitopes in the DSG3 EC1 domain. Consistently, 
PVA224 IP both the DSG3 mature form, in which the trans-adhe-
sive interface is accessible, and the higher molecular weight DSG3 
precursor, in which the trans-adhesive interface is not accessible, 
being masked by the presence of the propeptide (Supplemental 
Figure 3E). In contrast, AK23 IP only the mature form of DSG3. 
Using the same competition assay, we found that the 2 EC2-specif-
ic pathogenic antibodies PVB28 and PVB124 cross-competed for 
binding to DSG3, indicating that they recognize the same or over-
lapping regions of DSG3 EC2 (Supplemental Figure 3C).
To identify the epitopes recognized by the 3 human pathogenic anti-
bodies, we used PEPSCAN technology and screened libraries of DSG3 
EC1 and EC2 peptides comprising 15-mer linear peptides, 17-mer 
peptides looped by a disulfide bond, and double CLIPS (Chemical 
Linkage of Peptides onto Scaffolds) peptides locked into double loops 
by 3 disulfide bonds. The EC1-specific antibody PVA224 was found 
Figure 3
In vitro and in vivo pathogenic activity of anti-DSG3 antibodies. (A) Representative keratinocyte dissociation experiment. Primary human kera-
tinocytes were seeded to confluence, and mAb PVA224 and a control antibody were added (1–10 μg/ml), followed by addition of ETA to cleave 
DSG1 molecules. Cells were incubated with dispase I to detach the monolayer from the plate, and sheet fragments were fixed and stained using 
crystal violet. (B) Keratinocyte dissociation induced by different antibodies. Shown is the dissociation index determined as specified in Methods 
in duplicate cultures in 2 independent experiments (mean ± SEM). (C–E) Macroscopic blisters (black arrows) (C), intraepidermal suprabasal 
blistering and acantholysis (D), and intercellular deposition of human IgG in the epidermis (E) induced by injection into newborn mice of the 
indicated antibodies coadministered with ETA. Data are representative of results obtained from groups of 5 mice. Original magnification, ×200.
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to recognize a peptide from the linear library (KITYRISGVGIDQPP) 
and a conformation-dependent peptide from the double CLIPS 
library (RALNAQGLDVEKPLI). Since structural information of the 
DSG3 domains is not available, we aligned the DSG3 sequence with 
that of C-cadherin, for which structural information is available (ref. 
8 and Figure 4A). The positioning of the homologous peptides in the 
C-cadherin crystal structure defines the PVA224 epitope as a discon-
tinuous epitope located in the EC1 region on the opposite side of the 
trans-adhesive interface recognized by AK23 (Figure 4B). According to 
this mapping, PVA224 is expected to disrupt the EC1-EC2 interface 
involved in cis-interaction of cadherin molecules required to form lat-
eral strand dimers (8). Comparable results were obtained by modeling 
the peptides recognized by PVA224 on the DSG2 EC1 nuclear mag-
netic resonance (NMR) structure (data not shown).
The same approach was used to map the epitopes recognized 
by EC2-specific pathogenic antibodies PVB28 and PVB124. Pep-
tides recognized by PVB28 and PVB124 were identified in the 
double CLIPS library. Both antibodies bound to a CLIPS peptide 
(SKIAFKIVSQEPAGT), while PVB124 bound also 2 amino acid 
stretches located at the N terminus (DINDNPPV) and at the C 
terminus (ADKDGEGLSTQCECN) of the EC2 subdomain (Fig-
ure 4B). The location of the homologous peptides on C-cadherin 
defines 2 discontinuous overlapping epitopes in the EC2 region 
that are expected to interact in cis with the EC1 of the neighboring 
molecule (Figure 4B). The proximity of the 2 epitopes is consistent 
with finding that PVB28 and PVB124 cross-compete for binding to 
DSG3 (Supplemental Figure 3C). However, the ability of PVB28, 
and not of PVB124, to cross-react with mouse DSG3 indicates 
Figure 4
Epitope mapping of 3 pathogenic antibodies. (A) Alignment of DSG3 amino acid sequence 1–232 with C-cadherin, DSG1, DSG2, and DSG4. 
EC1, EC2, and EC3 subdomains are highlighted with red, blue, and orange boxes, respectively. Peptides recognized by PVA224 are highlighted 
in blue and pink, peptides recognized by PVB28 in green, and peptides recognized by PVB124 in light blue, red, and green. The reported amino 
acid residues bound by AK23 (13) are highlighted in yellow. (B) Location of peptides recognized by PVA224, PVB28, PVB124, and AK23 on the 
structure of C-cadherin ectodomain as determined in ref. 8. Color code is as above. The trans-adhesive interface is indicated by a gray double 
arrow. The cis-adhesive interfaces are indicated by orange double arrows.
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that the 2 antibodies recognize overlapping but different epitopes. 
Taken together, the above data indicate that the 3 human patho-
genic antibodies isolated target 2 novel sites on the EC1 and EC2 
subdomains of DSG3 that are part of the cis-adhesive EC1-EC2 
interface found in DSG3 arrays.
The PVA224 epitope is the main target of PV autoantibodies in human 
sera. To determine whether antibodies of the same specificity as the 
characterized antibodies were present in the sera of PV patients, we 
measured the capacity of serum antibodies to inhibit binding of 
human and mouse pathogenic antibodies to DSG3. ELISA plates 
were coated with DSG3 and incubated with PV or control sera, fol-
lowed by the addition of biotinylated AK23, PVA224, PVB124, or 
PVB28 antibodies, which were then detected using enzyme-labeled 
streptavidin. All PV sera tested, but not control sera, inhibited bind-
ing of PVA224 by more than 80%, consistent with the presence in the 
sera of antibodies against the cis-adhesive site targeted by PVA224 
(Figure 5A). In contrast, only 5, 3, and 4 out of 10 sera inhibited 
binding of AK23, PVB124, and PVB28, respectively, by at least 50%. 
The high prevalence of PVA224-like antibodies in PV 
patients was further supported by analysis of sera 
from 57 PV patients (Figure 5B). In contrast, such 
antibodies were absent in sera from patients with bul-
lous pemphigoid and healthy donors.
To estimate the fraction of total serum DSG3-
specific antibodies targeting the PVA224 and AK23 
sites, we measured the capacity of AK23 and of a 
“murinized” version of PVA224 to inhibit binding of 
human serum polyclonal antibodies to DSG3-coat-
ed plates. PVA224 inhibited binding of 8 out of 10 
PV sera with values ranging from 20% to 90%, while 
AK23 inhibited only 4 out of 10 PV sera (Figure 5C). 
Taken together, the above results indicate that the 
PVA224 site on DSG3 EC1 is an immunodominant 
target for pathogenic autoantibodies in PV patients, 
while sites defined by AK23 on EC1 and by PVB124 
and PVB28 on EC2 are subdominant, being targeted 
in some but not all patients.
Reversion of somatic mutations in VH but not VL genes 
abolishes binding to DSG3. To gain insights into the 
fundamental question on the nature of the immune 
response that led to the generation of pathogenic 
autoantibodies, we produced recombinant antibodies 
in which we removed all somatic mutations in the VH 
and VL genes of 3 pathogenic antibodies (PVA224, 
PVB28, and PVB124) and 1 nonpathogenic antibody (PVB16) and 
measured the capacity of these “germlined” antibodies (Supple-
mental Figure 4) to bind to DSG3. Strikingly and in contrast to the 
mutated antibodies, all the germlined antibodies failed to bind to 
DSG3 when tested by ELISA or IF on DSG3 transfectants or human 
skin (Figure 6, A and B, and Supplemental Figure 5). In addition, 
recombinant antibodies with mutated VH but germlined VL were 
capable of binding to DSG3, as the original antibody indicating that 
binding of the tested antibodies to DSG3 required somatic muta-
tion in the heavy but not in the light chain (Figure 6B). We conclude 
that in some antibodies isolated from PV patients, autoreactivity 
was acquired as a function of somatic mutation in the VH genes.
Discussion
In this study, we isolated pathogenic IgG autoantibodies from 2 
PV patients and demonstrated that these antibodies target the 
EC1 and EC2 subdomains of DSG3 in regions that are involved 
in cis-adhesive interactions. The finding that EC2 is targeted by 
Figure 5
The PVA224 site on DSG3 EC1 is an immunodominant 
target for pathogenic autoantibodies in PV patients. (A) 
The inhibitory capacity of 10 PV and 2 control sera on 
the binding of human (PVA224, PVB124, and PVB28) 
and mouse (AK23) pathogenic antibodies to DSG3. (B) 
The inhibitory capacity of patient or control sera to inhibit 
binding of PVA224 to DSG3. Sera from 57 PV patients, 
10 bullous pemphigoid (BP) patients, and 32 healthy 
donors (NHS) are shown. (C) The inhibitory capacity of 
murinized PVA224 (top) or mouse AK23 (bottom) on the 
binding of serum antibodies from 10 PV patients and 
2 controls. Cut-off value (dashed line) is the mean of 
inhibition value of the 40 control sera plus 2 SD. Similar 
results were obtained in 2 independent experiments.
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serum and pathogenic mAbs of pemphigus patients has been 
recently reported (20, 22), but the mAbs’ fine specificity has not 
been defined. Previous studies in a mouse model of PV led to the 
isolation and characterization of a mouse pathogenic antibody, 
AK23, that binds to EC1 and disrupts the DSG3-DSG3 trans-
adhesive interaction (13). Importantly, by analyzing PV sera for 
their capacity to inhibit binding to DSG3 of human and mouse 
pathogenic antibodies, we demonstrate that virtually all PV 
patients tested have serum antibodies to the cis-adhesive interface 
of EC1 (defined by PVA224), while a subset of patients have anti-
bodies to the trans-adhesive interface of EC1 (defined by AK23) 
or to the cis-adhesive interface of EC2 (defined by PVB124). These 
findings not only identify an immunodominant site targeted by 
pathogenic PV autoantibodies, but also suggest a mechanism of 
blister formation in PV. Availability of DSG3 crystal structure and 
further functional studies are needed to confirm this hypothesis.
A body of experimental evidence supports the essential role of 
lateral cadherin dimerization, in addition to trans-interaction, in 
mediating cell-cell adhesion (23, 24). In addition, recent studies 
have shown that PV-IgG treatment of keratinocytes causes inter-
nalization of nondesmosomal DSG3 clusters, resulting in the 
formation of DSG3-depleted desmosomal complexes and loss of 
cell-cell adhesion (25–28). These observations are in line with ini-
tial electron microscopy studies demonstrating that keratinocytes 
separate first in the interdesmosomal areas of early PV lesions, 
when desmosomes are intact and still adhere to each other (29, 
Figure 6
DSG3 autoreactivity is determined by somatic mutations in the VH genes. Four antibodies were produced recombinantly in the original VH/VL 
somatically mutated version (VHSM-VLSM), in a full germlined VH/VL version (VHGL-VLGL), or a VH only or VL only germlined version (VHGL-VLSM 
or VHSM-VLGL, respectively). The antibodies were tested for staining of 293T cells transfected with DSG3 gene (A) and binding to DSG3-coated 
plates as assessed by ELISA (B). Representative experiment out 3 independent experiments performed. The low binding of the germlined PVB28 
was also observed on uncoated plates and can be explained by a low degree of polyspecificity.
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30). Thus, it is tempting to suggest that pathogenic antibodies 
could interfere with DSG3-DSG3 cis-interaction in the nondes-
mosomal as well as in the desmosomal compartment.
Another major finding of this study is the demonstration, for 
what we believe is the first time in an organ-specific autoimmune 
disease, that the germline version of the autoantibodies does 
not recognize the nominal autoantigen. Furthermore, at vari-
ance with previous studies (14, 31), we show that the response is 
polyclonal and that the autoantibodies use different VH and VL 
and all IgG isotypes. The finding that replacing mutations are 
mainly found in the CDRs is suggestive of antigenic selection, 
and in the 4 pathogenic antibodies studied in more detail, we 
have shown that the replacing mutations responsible for DSG3 
reactivity lay in the VH, a finding that is reminiscent of a pre-
vious report describing a consensus sequence in the CDR3 of 
pathogenic antibodies (32).
The finding that germlined autoantibodies do not bind DSG3 
suggests that this autoantigen does not represent the primary 
trigger of the pathogenic B cell clones. Somatic mutations are 
known to expand the B cell repertoire by intraclonal B cell recep-
tor (BCR) diversification in the memory compartment (33). A role 
for somatic mutation in development of autoantibodies has been 
initially demonstrated in the mouse system (34, 35), and more 
recent studies using germlined antibodies have extended these 
observations to the human system. In particular, 2 anti-DNA auto-
antibodies isolated from SLE patients were found to be derived 
from nonautoreactive B cells, suggesting that they developed as a 
byproduct of a normal immune response (36). Furthermore, it was 
shown that in healthy individuals, a substantial fraction of IgG 
memory B cells express self-reactive and polyreactive specificities 
that develop by somatic mutations and are absent in bone marrow 
plasma cells (37, 38). We found that, with the exception of PVB28, 
the germlined antibodies were not polyreactive, suggesting that 
their selection was not driven by heteroligation, as suggested for 
HIV-neutralizing antibodies (39). However, we cannot rule out the 
possibility that the germlined antibodies might have an affinity 
for DSG3 sufficient to trigger naive B cells, but insufficient to be 
detected in classical binding assays.
The derivation of autoantibodies from an ongoing immune 
response to an unrelated antigen through fortuitous mutations 
introducing self reactivity represents a plausible mechanism for the 
generation of humoral autoimmunity. The low activation thresh-
old of activated and memory B cells and their capacity to proliferate 
and differentiate in the absence of T cell help (40, 41) may be the 
basis for the selection of autoreactive clones. The finding that PV 
autoantibodies characterized in this study belong to all IgG class-
es, in particular IgG4, would be consistent with their derivation 
from distinct types of ongoing chronic immune responses that are 
known to elicit IgG4 antibody production (42). However, it is also 
possible that the pathogenic antibodies might have derived from 
the antibody response to a particular foreign antigen.
In conclusion, the characterization of pathogenic mAbs points 
to the disruption of DSG3 cis-interaction as a possible mecha-
nism underlying blister formation in PV. The identification of 
an immunodominant region targeted by pathogenic antibodies 
has implications for diagnosis of PV and opens new perspectives 
toward the establishment of therapeutic approaches for treatment 
of PV patients. Finally, the germlined version of the PV autoanti-
bodies may lead to the identification of the antigens that eventu-
ally lead to development of this life-threatening disease.
Methods
Isolation of monoclonal autoantibodies from PV patients. Peripheral blood sam-
ples were obtained from 2 patients (PVA and PVB) suffering from active 
mucocutaneous PV. The patients showed typical clinical, histological, and 
immunopathological features and had high-titer anti-DSG circulating 
autoantibodies (PVA: DSG3, 308 U/ml, DSG1, 110 U/ml; PVB: DSG3, 191 
U/ml, DSG1, 170 U/ml), as assessed by ELISA kits based on ectodomain of 
DSG1 and DSG3 (MBL). IgG+ memory B cells were isolated from cryopre-
served PBMC using CD22 microbeads (Miltenyi Biotec) followed by deple-
tion of cells carrying IgM, IgD, and IgA by cell sorting. Multiple replicate 
microcultures of 10–30 IgG+ memory B cells/well (for a total of 2 to 8 × 104 
purified cells) were infected with EBV and CpG as previously described 
(15). Culture supernatants were tested for binding to DSG3-coated ELISA 
plates and for binding to the keratinocyte cell line (HaCaT) monolayers by 
IF assay using an automated fluorescence microscope (Pathway 855; BD). 
The specificity of positive polyclonal cultures was further assessed by IF on 
primary human keratinocytes and by ELISA on recombinant DSG1. Posi-
tive reactivities detected (0.17% and 2.12% of memory B cell seeded for PVA 
and PVB, respectively) were confirmed by the propagation of oligoclonal 
cultures. Positive cultures were cloned by limiting dilution and expanded; 
antibodies were purified using protein G columns. Specific mAbs could be 
isolated only from a fraction of the initial hits (12% in PVA and 20% in PVB).
IF studies. Supernatants from immortalization cultures or cloned 
B cells were tested by IF staining for their binding to live HaCaT and 
primary human keratinocytes. Cells were seeded at 2 × 104 cells/cm2 in 
flat-bottom 384- or 96-well plates and were grown to confluence. Conflu-
ent monolayers were grown for an additional 16 hours in fresh medium 
supplemented with 1.2 mM CaCl2. IF staining was performed on cell 
monolayers in their culture plates. Cells were washed in PBS and incubated 
for 0.5 hours at room temperature (RT) with B cell culture supernatants, 
washed, and stained for an additional 0.5 hours with Alexa Fluor 488–con-
jugated goat anti-human IgG (Invitrogen). Human antibodies of irrelevant 
specificity were used as negative controls. Murine AK23 antibody, revealed 
by Alexa Fluor 488–conjugated goat anti-mouse IgG, was used as a positive 
control. Serial images of stained keratinocyte monolayers were acquired 
by the BD Pathway 855 automated fluorescence microscope. Staining 
was also performed on cryosections of monkey esophagus and human or 
mouse skin. Cryosections of skin of neonatal mice injected with patho-
genic antibodies were blocked with PBS containing 3% BSA and stained 
with FITC-conjugated rabbit anti-human IgG (DAKO).
ELISA assays. Recombinant proteins DSG3(aa 1–566) and DSG1(aa 
1–496) were produced in baculovirus and affinity purified as previously 
reported (2). ELISA plates were coated with DSG1 and DSG3, blocked with 
1% BSA, and incubated with antibodies followed by HRP-conjugated anti-
human IgG Fcγ fragment-specific secondary antibodies (Jackson Immu-
noResearch). For mapping of calcium-dependent conformational epitopes, 
domain-swapped DSG3 recombinant molecules (DSG3 EC1–EC5 in the 
backbone of DSG2) were used (20, 43). Limiting antibody concentrations 
were incubated with an excess of baculovirus culture supernatant con-
taining a single swapped molecule and tested for their capacity to bind to 
DSG3-coated plates. To measure sensitivity to calcium depletion, wells coat-
ed with DSG3 were incubated in the presence or absence of 10 mM EDTA 
and developed as described above. To determine the epitope specificity of 
serum antibodies, sera from PV patients or controls were tested at a fixed 
dilution (1:25) for their capacity to inhibit binding of limiting amounts 
of biotinylated human antibodies (or mouse AK23 or murinized PVB224 
antibodies) to DSG3-coated plates. The capacity of mAbs to inhibit binding 
of polyclonal serum antibodies was measured by adding to DSG3 ELISA 
plates murinized PVA224 or AK23 antibodies first, followed by PV sera and 
anti-human secondary reagents. The cut-off value was calculated as the 
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mat in which the colored substrate was quantified with a charge-coupled 
device (CCD) camera and an image-processing system. The values mostly 
ranged from 0 to 3,000, a log scale similar to 1 to 3 of a standard 96-well 
plate ELISA reader.
Keratinocyte dissociation assay. The ability of antibodies to dissociate kera-
tinocyte monolayers was measured according to Ishii et al (21). Primary 
human keratinocytes were seeded onto 12-well plates in KGM medium 
(Lonza) containing 0.15 mM CaCl2. Forty-eight hours after confluence, the 
medium was changed to 1.2 mM CaCl2 and mAbs were added (1–10 μg/ml) 
at 37°C overnight followed by addition of ETA (1 μg/ml) to cleave DSG1 
molecules. After washing, the cells were incubated with dispase I (Roche 
Diagnostics Corp) for 30 minutes to detach the monolayer from the plate. 
Released cell sheets were washed with PBS twice and subject to mechanical 
stress by pipetting. The sheet fragments were fixed by adding formaldehyde 
at a final concentration of 3% and stained using crystal violet. The num-
ber of fragments was determined as an average of the number of fragments 
counted by using 3 sets of images captured by a digital camera for each plate. 
The dissociation index was calculated with the following formula: (Ab – C–)/
(C+ – C–) × 100, where C+ is AK23 and C– an irrelevant control antibody.
Passive transfer model. The pathogenic activity of antibodies was evaluated 
by passive transfer in neonatal mice (4). Human antibodies (300 μg/mouse) 
were injected subcutaneously into the backs of neonatal C57BL/6NCrl 
mice together with 2 μg ETA, which specifically cleaves DSG1. Controls 
were injected with the same dose of normal human IgG, PBS, or ETA alone. 
Mice were sacrificed 18 to 24 hours after injection. Skin was harvested for 
direct IF analysis and for histology.
Statistics. P value cutoff used to determine statistical significance in the 
analysis for positive or negative antigenic selection using the Focus and 
Global binomial tests was 0.05. Data were analyzed using GraphPad Prism 
software.
Study approval. The study was conducted in accordance with the Decla-
ration of Helsinki guidelines and was approved by the IDI-IRCCS Ethics 
Committee; all patients gave informed consent.
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mean of inhibition value of the 30 control (normal human serum [NHS]) 
and 10 sera from bullous pemphigoid patients plus 2 SDs. The competition 
between unlabeled and biotinylated or “murinized” mAbs was measured by 
adding to DSG3-coated plates first unlabeled competitor antibodies at dif-
ferent concentrations, followed by the labeled antibodies added at a concen-
tration corresponding to 70%–80% of the maximal OD level. Bound labeled 
antibodies were detected using alkaline phosphatase–labeled (AP-labeled) 
streptavidin (for biotynilated antibody) or AP-labeled anti-mouse IgG (Jack-
son Immunoresearch). Samples were tested in duplicates, and percentage of 
inhibition was calculated as follow: (1 – [(OD sample – OD negative control)/
(OD positive control – OD negative control)]) × 100.
Immunoprecipitation studies. In selected cases, mapping results by ELISA 
were confirmed by IP studies. Briefly, baculovirus culture supernatants 
containing specific domain-swapped baculoproteins (DSG3 EC1–EC5/
DSG2) and DSG2 and DSG3 as controls were incubated at RT for 1 hour 
with each antibody. As all the constructs were E-tagged, and an anti–E-tag 
polyclonal antibody (Bethyl) was used as a positive control. The protein-
antibody complex was incubated with protein A/G PLUS Agarose (Santa 
Cruz Biotechnology Inc.) at 4°C overnight. Centrifuged IPs were applied to 
SDS-PAGE and blotted onto a polyvinylidene difluoride membrane (Milli-
pore). To detect IP recombinant proteins, membranes were first incubated 
with the anti–E-tag rabbit polyclonal antibody and then with a secondary 
AP-conjugated anti-rabbit IgG antibody (SouthernBiotech). The filter was 
washed and stained with 330 mg/ml of nitroblue tetrazolium (NBT) and 
165 mg/ml of 5-bromo-4-chloro-3-indolyl phosphate (BCIP) (Roche Diag-
nostics Corp.) in substrate buffer (100 mM NaCl, 100 mM Tris-HCl, pH 
9.6, 5 mM MgSO4). The same IP procedure was applied to IP the precursor 
and/or mature form of DSG3 using recombinant baculoprotein produced 
and affinity purified as previously reported (2).
Antibody purification, labeling, genetic analysis, and reversion to germline. 
Human mAbs were affinity purified by protein A or protein G chromatog-
raphy (GE Healthcare) and desalted against PBS. Selected antibodies were 
biotinylated using the EZ-Link NHS-PEO Solid Phase Biotinylation Kit 
(Pierce). The “murinization” of human antibodies was performed by clon-
ing the VH and VL/VK genes into expression vectors containing human 
IgG1, Igκ, and Igλ constant regions in which the human constant region 
(hinge, CH2, and CH3 domains) was replaced by the homologous mouse 
IgG2a. Recombinant antibodies were produced by transient transfection 
of 293 Freestyle Cells (Invitrogen) using polyethylenimine (PEI). The usage 
of VH and VL gene segments was determined by sequencing, and analysis 
for homology to known human V, D, and J genes was performed using 
the IMGT (international ImMunoGeneTics information system) data-
base (44). The analysis for the presence of positive or negative antigenic 
selection for VH and VK/VL mutated gene segments was performed using 
both the Focused and Global tests for comparison (http://clip.med.yale.
edu/selection), as described (18). Germlined sequences were determined 
by reverting mutations to the germline sequence while retaining the origi-
nal CDR3 junctions and terminal deoxy-nucleotidyl transferase (TdT) N 
nucleotides. Germlined VH and VL nucleotide sequences were synthesized 
by Genscript, and their accuracies were confirmed by sequencing.
Epitope mapping. Overlapping linear 15-mer, cyclized 17-mer, and double 
CLIPS locked into double loops by 3 disulfide bond peptides based on 
EC1 and EC2 DSG3 were synthesized on polypropylene support (mini-
cards) and were tested for reactivity with antibodies as described (45). 
Pepscan peptide-binding analysis was carried out by an ELISA-based for-
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